Skip to main
GMED
GMED logo

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc. is positioned for potential growth driven by faster-than-expected expansion in the spine market, increased sales in Enabling Technologies, and improved margins. The company has demonstrated impressive free cash flow (FCF) growth and an attractive FCF yield of 8%, indicating solid financial health despite current stock trading below historical valuation levels. Additionally, even with slight revenue misses in Q2 2025, the firm is expected to experience profit upside well into future years, suggesting a favorable outlook for investors.

Bears say

Globus Medical faces substantial risks that could negatively impact its financial performance, including slower growth in the spine market, revenue dis-synergies from the recent NuVasive merger, and disappointing sales in its Enabling Technologies segment. The company's outlook suggests potential revenue growth slowing to low-single digits, which would limit opportunities for margin expansion and indicate a decline in operational efficiency. Concerns over competitive dynamics, delayed product launches, and a challenging capital environment for robotic purchases further exacerbate the uncertainties surrounding Globus Medical’s financial outlook.

Globus Medical (GMED) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 11 analysts, Globus Medical (GMED) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.